한글목차

GSK3228836(베피로비르센)은 글락소 스미스클라인(GSK)과 아이오니스 파마(Ionis Pharma)의 공동 개발품입니다. 베피로비르센은 B형 간염 바이러스가 감염된 간세포(간세포)에서 자가복제하고 면역체계의 제거를 피하고 질병의 만성화를 촉진하는 바이러스 항원(단백질)을 만드는 데 사용하는 RNA를 특이적으로 인식하도록 설계된 임상 중인 항센스 올리고뉴클레오티드(ASO)입니다. ASO)입니다. 베피로비르센은 Toll-like receptor 8(TLR8)을 통해 면역 반응을 자극하는 특성을 가지고 있어 면역계가 순환 혈액에서 바이러스를 지속적으로 제거하는 데 도움을 줄 수 있습니다.

GSK3528869A는 3성분 치료용 백신입니다.

앞으로 몇 년동안 만성 B형 간염 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질병을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, GSK3528869A-베피로비르센의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 만성 B형간염에 대한 다른 신흥 제품들이 GSK3528869A-베피로비르센과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의과 중국의 만성 B형 간염 치료제 GSK3528869A+-베피로비르센(GSK3528869A) 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 만성 B형 간염 치료제 GSK3528869A+-베피로비르센 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 GSK3528869A+-베피로비르센 시장 평가

• 만성 B형 간염 치료제GSK3528869A+-베피로비르센 시장 전망
• 주요 7개국과 중국 분석
  • 주요 7개국 및 중국의 만성 B형 간염 치료제 GSK3528869A+-베피로비르센 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국
  • 중국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"GSK3528869A +- Bepirovirsen Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about GSK3528869A +- Bepirovirsen for chronic hepatitis B in the seven major markets and China. A detailed picture of the GSK3528869A +- Bepirovirsen for chronic hepatitis B in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China for the study period 2019 -2032 is provided in this report along with a detailed description of the GSK3528869A +- Bepirovirsen for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the GSK3528869A +- Bepirovirsen market forecast analysis for chronic hepatitis B in the 7MM and China, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary:

GSK3228836 (also known as bepirovirsen) is under the developmental process of the collaboration of GlaxoSmithKline (GSK) and Ionis Pharma. It is an investigational antisense oligonucleotide (ASO) designed to specifically recognize the RNA that the hepatitis B virus uses to replicate itself in the infected liver cells (hepatocytes) and make the viral antigens (proteins) that facilitate chronicity of the disease by helping to avoid clearance by the immune system. Bepirovirsen has the additional property of stimulating immune responses via Toll-like receptor 8 (TLR8), which may help the immune system to achieve durable clearance of the virus from circulating blood.

GSK3528869A is a three-component therapeutic vaccine:

• ChAd155-hIi-HBV: replication-defective simian (chimpanzee-derived) Group C adenovirus serotype 155 viral vector encoding sequences of two HBV protein antigens: the truncated hepatitis B core antigen (HBcAg) and the full-length small hepatitis B surface antigen (S-HBsAg)
• MVA-HBV: encoding the above two HBV protein antigens Modified vaccinia Ankara (MVA), which is a highly attenuated vaccinia virus strain
• HBc-HBs/AS01B-4: the above two HBV protein antigens enhanced by the AS01B-4 adjuvant, which is a liposomal combination of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella minnesota and a saponin molecule (QS-21) from plant extract of Quillaja saponaria.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the GSK3528869A +- Bepirovirsen description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on GSK3528869A +- Bepirovirsen regulatory milestones and other development activities have been provided in this report.
• The report also highlights the GSK3528869A +- Bepirovirsen research and development activities in chronic hepatitis B across the United States, Europe, Japan, and China.
• The report also covers the patents information with expiry timeline around GSK3528869A +- Bepirovirsen.
• The report contains forecasted sales of GSK3528869A +- Bepirovirsen for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for GSK3528869A +- Bepirovirsen in chronic hepatitis B.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GSK3528869A +- Bepirovirsen Analytical Perspective by DelveInsight

• In-depth GSK3528869A +- Bepirovirsen Market Assessment

This report provides a detailed market assessment of GSK3528869A +- Bepirovirsen for chronic hepatitis B in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China. This segment of the report provides forecasted sales data from 2029 to 2032.

• GSK3528869A +- Bepirovirsen Clinical Assessment

The report provides the clinical trials information of GSK3528869A +- Bepirovirsen for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence GSK3528869A +- Bepirovirsen dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to GSK3528869A +- Bepirovirsen and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GSK3528869A +- Bepirovirsen in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of GSK3528869A +- Bepirovirsen from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GSK3528869A +- Bepirovirsen in chronic hepatitis B.

Key Questions:

• What is the product type, route of administration and mechanism of action of GSK3528869A +- Bepirovirsen?
• What is the clinical trial status of the study related to GSK3528869A +- Bepirovirsen in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GSK3528869A +- Bepirovirsen development?
• What are the key designations that have been granted to GSK3528869A +- Bepirovirsen for chronic hepatitis B?
• What is the forecasted market scenario of GSK3528869A +- Bepirovirsen for chronic hepatitis B?
• What are the forecasted sales of GSK3528869A +- Bepirovirsen in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China?
• What are the other emerging products available and how are these giving competition to GSK3528869A +- Bepirovirsen for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

Table of Contents

1. Report Introduction

2. GSK3528869A +- Bepirovirsen Overview in Chronic hepatitis B

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. GSK3528869A +- Bepirovirsen Market Assessment

• 5.1. Market Outlook of GSK3528869A +- Bepirovirsen in Chronic hepatitis B
• 5.2. 7MM and China Analysis
  • 5.2.1. Market Size of GSK3528869A +- Bepirovirsen in the 7MM and China for Chronic hepatitis B
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of GSK3528869A +- Bepirovirsen in the United States for Chronic hepatitis B
  • 5.3.2. Market Size of GSK3528869A +- Bepirovirsen in Germany for Chronic hepatitis B
  • 5.3.3. Market Size of GSK3528869A +- Bepirovirsen in France for Chronic hepatitis B
  • 5.3.4. Market Size of GSK3528869A +- Bepirovirsen in Italy for Chronic hepatitis B
  • 5.3.5. Market Size of GSK3528869A +- Bepirovirsen in Spain for Chronic hepatitis B
  • 5.3.6. Market Size of GSK3528869A +- Bepirovirsen in the United Kingdom for Chronic hepatitis B
  • 5.3.7. Market Size of GSK3528869A +- Bepirovirsen in Japan for Chronic hepatitis B
  • 5.3.8. Market Size of GSK3528869A +- Bepirovirsen in China for Chronic hepatitis B

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options